-
Something wrong with this record ?
Posttreatment with group II metabotropic glutamate receptor agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate is only weakly effective on seizures in immature rats
J. Folbergrová, R. Druga, G. Tsenov, R. Haugvicová, J. Otáhal
Language English Country Netherlands
Document type Research Support, Non-U.S. Gov't
NLK
ScienceDirect (archiv)
from 1993-01-01 to 2009-12-31
- MeSH
- Excitatory Amino Acid Agonists therapeutic use MeSH
- Cytoprotection physiology drug effects MeSH
- Nerve Degeneration chemically induced physiopathology prevention & control MeSH
- Epilepsy drug therapy metabolism physiopathology MeSH
- Hippocampus metabolism growth & development drug effects MeSH
- Homocysteine analogs & derivatives pharmacology MeSH
- Convulsants pharmacology MeSH
- Rats MeSH
- Drug Interactions physiology MeSH
- Brain metabolism growth & development drug effects MeSH
- Neuroprotective Agents therapeutic use MeSH
- Rats, Wistar MeSH
- Proline analogs & derivatives therapeutic use MeSH
- Receptors, Metabotropic Glutamate agonists metabolism MeSH
- Drug Administration Schedule MeSH
- Aging metabolism MeSH
- Thalamus metabolism growth & development drug effects MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
The present study has examined the anticonvulsant and neuroprotective effect of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC), a selective agonist for group II metabotropic glutamate receptors (mGluRs) when given 10-15 min after the onset of seizures induced in 12-day-old rats by bilateral icv infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side). For biochemical analyses, rat pups were sacrificed during generalized clonic-tonic seizures, approximately 45-50 min after infusion of DL-HCA. Comparable time intervals were used for sacrificing the animals which received 2R,4R-APDC (0.05 nmol/side) or saline. The severity of seizures was influenced only slightly when the agonist was given after the onset of seizures, as evaluated both from the behavioral symptoms and from EEG recordings. A tendency to lower number and a shorter duration of seizures was outlined in animals posttreated with 2R,4R-APDC, but the differences did not reach the level of statistical significance. Cortical energy metabolite changes which normally accompany seizures in immature rats (large decrease of glucose and glycogen and a marked rise of lactate) were ameliorated only partially. The neuroprotective effect of 2R,4R-APDC was evaluated after 24 h and 6 days of survival following DL-HCA-induced seizures. Massive neuronal degeneration in many brain regions, mainly in the hippocampus and thalamus, following infusion of DL-HCA alone was only partially attenuated after 2R,4R-APDC posttreatment. The present findings clearly indicate that both anticonvulsant and neuroprotective effect of 2R,4R-APDC against DL-HCA-induced seizures is substantially diminished when the agonist is given after the onset of seizures as compared with its efficacy after the pretreatment (Exp. Neurol.192, 420-436, 2005).
- 000
- 04489naa 2200661 a 4500
- 001
- bmc11017096
- 003
- CZ-PrNML
- 005
- 20121127121233.0
- 008
- 110629s2009 ne e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Folbergrová, Jaroslava, $d 1932- $7 jn20000400705
- 245 10
- $a Posttreatment with group II metabotropic glutamate receptor agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate is only weakly effective on seizures in immature rats / $c J. Folbergrová, R. Druga, G. Tsenov, R. Haugvicová, J. Otáhal
- 314 __
- $a Institute of Physiology, v.v.i., Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Prague 4, Czech Republic. folbergr@biomed.cas.cz
- 520 9_
- $a The present study has examined the anticonvulsant and neuroprotective effect of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC), a selective agonist for group II metabotropic glutamate receptors (mGluRs) when given 10-15 min after the onset of seizures induced in 12-day-old rats by bilateral icv infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side). For biochemical analyses, rat pups were sacrificed during generalized clonic-tonic seizures, approximately 45-50 min after infusion of DL-HCA. Comparable time intervals were used for sacrificing the animals which received 2R,4R-APDC (0.05 nmol/side) or saline. The severity of seizures was influenced only slightly when the agonist was given after the onset of seizures, as evaluated both from the behavioral symptoms and from EEG recordings. A tendency to lower number and a shorter duration of seizures was outlined in animals posttreated with 2R,4R-APDC, but the differences did not reach the level of statistical significance. Cortical energy metabolite changes which normally accompany seizures in immature rats (large decrease of glucose and glycogen and a marked rise of lactate) were ameliorated only partially. The neuroprotective effect of 2R,4R-APDC was evaluated after 24 h and 6 days of survival following DL-HCA-induced seizures. Massive neuronal degeneration in many brain regions, mainly in the hippocampus and thalamus, following infusion of DL-HCA alone was only partially attenuated after 2R,4R-APDC posttreatment. The present findings clearly indicate that both anticonvulsant and neuroprotective effect of 2R,4R-APDC against DL-HCA-induced seizures is substantially diminished when the agonist is given after the onset of seizures as compared with its efficacy after the pretreatment (Exp. Neurol.192, 420-436, 2005).
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a stárnutí $x metabolismus $7 D000375
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozek $x metabolismus $x růst a vývoj $x účinky léků $7 D001921
- 650 _2
- $a konvulziva $x farmakologie $7 D003292
- 650 _2
- $a cytoprotekce $x fyziologie $x účinky léků $7 D019610
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a lékové interakce $x fyziologie $7 D004347
- 650 _2
- $a epilepsie $x farmakoterapie $x metabolismus $x patofyziologie $7 D004827
- 650 _2
- $a agonisté excitačních aminokyselin $x terapeutické užití $7 D018690
- 650 _2
- $a hipokampus $x metabolismus $x růst a vývoj $x účinky léků $7 D006624
- 650 _2
- $a homocystein $x analogy a deriváty $x farmakologie $7 D006710
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a degenerace nervu $x chemicky indukované $x patofyziologie $x prevence a kontrola $7 D009410
- 650 _2
- $a neuroprotektivní látky $x terapeutické užití $7 D018696
- 650 _2
- $a prolin $x analogy a deriváty $x terapeutické užití $7 D011392
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptory metabotropního glutamátu $x agonisté $x metabolismus $7 D018094
- 650 _2
- $a thalamus $x metabolismus $x růst a vývoj $x účinky léků $7 D013788
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Druga, Rastislav, $d 1940- $7 nlk19990073109
- 700 1_
- $a Tsenov, Grigorij, $d 1980- $7 xx0103054
- 700 1_
- $a Haugvicová, Renata $7 xx0030584
- 700 1#
- $a Otáhal, Jakub. $7 xx0105144
- 773 0_
- $t Brain Research $w MED00000841 $g Roč. 1273(2009), s. 144-154
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110720101211 $b ABA008
- 991 __
- $a 20121127121259 $b ABA008
- 999 __
- $a ok $b bmc $g 864159 $s 726891
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00000841 $b 1273 $d 144-154 $m Brain research $n Brain Res
- LZP __
- $a 2011-3B09/BBjvme